fig1

Figure 1. Fra-1 is closely associated with chemoresistance in GC. (A) Fra-1 expression in the STAD dataset analyzed using box plots from the GEPIA2 database. T, tumor samples (n = 408 cases); N, normal samples (n = 211 cases); (B) Kaplan-Meier Plotter survival curves showing the distribution of OS in GC patients with high/low expression of Fra-1 in the STAD cohort; (C) Wayne plots demonstrating differentially expressed genes common to GC drug resistance datasets GSE192631, GSE236987, and GSE186205; (D-G) Cell proliferation ability of GC cells after overexpression/silencing of Fra-1 and treatment with CDDP detected using the CCK8 Cell Proliferation Detection Kit; (H-K) Cell proliferation ability of GC cells after overexpression/silencing of Fra-1 and treatment with CDDP (10 μM) detected using the EDU cell proliferation detection kit. Scale bar = 50 μm; (L) Statistical graph of semi-quantitative results of EDU fluorescence values in GC cells. All experiments were performed with three technical replicates. ^*P < 0.05; ^**P < 0.01; ^***P < 0.001. Fra-1: Fos-related antigen-1; GC: gastric cancer; OS: overall survival; CDDP: cisplatin; CCK8: cell counting kit-8; EDU: 5-ethynyl-2’-deoxyuridine.